TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025
Portfolio Pulse from
TScan Therapeutics is advancing its TSC-101 treatment for hematological malignancies, with key data from the phase 1 ALLOHA study expected by the end of 2025. The company plans a pivotal study for AML, MDS, and ALL patients undergoing HSCT in the second half of 2025, pending regulatory feedback. Additionally, TScan is developing multiplex TCR-Ts for solid tumors, with phase 1 PLEXI-T trial data anticipated in late 2025.
March 07, 2025 | 4:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TScan Therapeutics is progressing with its TSC-101 treatment for hematological malignancies, with significant data expected by the end of 2025. The company plans a pivotal study for AML, MDS, and ALL patients undergoing HSCT in the second half of 2025, subject to regulatory feedback. Additionally, TScan is developing multiplex TCR-Ts for solid tumors, with phase 1 PLEXI-T trial data anticipated in late 2025.
The news highlights TScan's progress in developing TSC-101 and multiplex TCR-Ts, with significant data expected by 2025. This could lead to pivotal studies and potential regulatory approvals, positively impacting TCRX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100